Next Article in Journal
Impact of the COVID-19 Outbreak on Adjuvant Chemotherapy for Patients with Stage II or III Colon Cancer: Experiences from a Multicentre Clinical Trial in China
Previous Article in Journal
Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery: A Clinical Practice Guideline
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 3
10.3747/co.27.6059
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer

by
D. Tiberi
1,
P. Vavassis
1,
D. Nguyen
1,
M.C. Guilbert
2,
A. Simon-Cloutier
3,
P. Dubé
3,
M.K. Gervais
3,
L. Sideris
3,
G. Leblanc
3,
T. Hijal
4,
M.P. Dufresne
5 and
M. Yassa
1,*
1
Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada
2
Department of Pathology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada
3
Department of Surgery, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada
4
Department of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada
5
Department of Radiology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(3), 155-158; https://doi.org/10.3747/co.27.6059
Submission received: 3 March 2020 / Revised: 5 April 2020 / Accepted: 7 May 2020 / Published: 1 June 2020

Abstract

Introduction: Standard treatment for early-stage invasive breast cancer (bca) consists of breast-conserving surgery and several weeks of adjuvant radiotherapy (rt). Neoadjuvant single-fraction rt is a novel approach for early-stage bca. We sought to investigate the effect of delaying surgery after neoadjuvant rt with respect to the rate of pathologic response (pr). Methods: Women 65 years of age or older with a new diagnosis of stage i luminal A bca were eligible for inclusion. A single 20 Gy dose to the primary breast tumour was given, followed by breast-conserving surgery 3 months later. The primary endpoint was the pr rate assessed by microscopic evaluation using the Miller–Payne system. Results: To date, 10 patients have been successfully treated. Median age of the patients was 72 years (range: 65–84 years). In 8 patients, neoadjuvant rt resulted in a tumour pr with median residual cellularity of 3%. No immediate rt complications other than mild dermatitis were noted. Conclusions: This study demonstrates a method for delivering single-fraction rt that can lead to a high level of pr in most patients. Continued accrual to this study and subsequent trials are needed to determine the feasibility, safety, and role of this novel technique in the management of early-stage bca.
Keywords: breast cancer; preoperative radiotherapy; sbrt; sabr; radiosurgery; ablative radiotherapy breast cancer; preoperative radiotherapy; sbrt; sabr; radiosurgery; ablative radiotherapy

Share and Cite

MDPI and ACS Style

Tiberi, D.; Vavassis, P.; Nguyen, D.; Guilbert, M.C.; Simon-Cloutier, A.; Dubé, P.; Gervais, M.K.; Sideris, L.; Leblanc, G.; Hijal, T.; et al. Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer. Curr. Oncol. 2020, 27, 155-158. https://doi.org/10.3747/co.27.6059

AMA Style

Tiberi D, Vavassis P, Nguyen D, Guilbert MC, Simon-Cloutier A, Dubé P, Gervais MK, Sideris L, Leblanc G, Hijal T, et al. Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer. Current Oncology. 2020; 27(3):155-158. https://doi.org/10.3747/co.27.6059

Chicago/Turabian Style

Tiberi, D., P. Vavassis, D. Nguyen, M.C. Guilbert, A. Simon-Cloutier, P. Dubé, M.K. Gervais, L. Sideris, G. Leblanc, T. Hijal, and et al. 2020. "Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer" Current Oncology 27, no. 3: 155-158. https://doi.org/10.3747/co.27.6059

APA Style

Tiberi, D., Vavassis, P., Nguyen, D., Guilbert, M. C., Simon-Cloutier, A., Dubé, P., Gervais, M. K., Sideris, L., Leblanc, G., Hijal, T., Dufresne, M. P., & Yassa, M. (2020). Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer. Current Oncology, 27(3), 155-158. https://doi.org/10.3747/co.27.6059

Article Metrics

Back to TopTop